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With the widespread introduction of optimal reperfu-sion therapy for the management of ST-segment–
elevation acute myocardial infarction (AMI), and significant 
advances in the treatment of non–ST-segment–elevation 
acute coronary syndromes, greater numbers of patients 
survive an acute infarct but remain at risk of developing 
heart failure. After acute myocardial injury, even if coro-
nary blood flow is promptly restored, a series of mechani-
cal and neurohormonal triggers may precipitate geometric 
changes that result in progressive left ventricular (LV) dila-
tation and dysfunction, leading ultimately to heart failure 
and premature death; this process is termed remodeling.1–4 
Attenuation (or even reversal) of LV remodeling is already 
a major focus in the management of survivors of acute coro-
nary syndromes.
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Galectin-3 is a β-galactoside–binding lectin secreted by 
activated macrophages, which has gained interest as at least a 
marker of, or possibly even a potential mediator in inflammation 
and fibrosis, processes that are central to the pathophysiology 
of LV remodeling.5,6 Upregulation of galectin-3 expression 
has been demonstrated in murine models of hypertensive 
heart disease, myocarditis and cardiomyopathy, and in the 
hypertrophied ventricular myocardium of humans with 
aortic stenosis and depressed LV systolic function.7–9 Serum 
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Background—Galectin-3 is a biomarker associated with inflammation and fibrosis that predicts adverse outcome and 
relates to biomarkers of extracellular matrix turnover in patients with heart failure, particularly when left ventricular 
(LV) systolic function is preserved. Whether galectin-3 is related to LV remodeling after acute myocardial infarction is 
unknown.
Methods and Results—Circulating galectin-3 and various extracellular matrix biomarkers were measured in 100 patients 
(age, 58.9±12.0 years; 77% men) admitted with acute myocardial infarction and LV dysfunction, at baseline (mean 
46 hours) and at 24 weeks, with cardiac MRI at each time-point. LV remodeling was defined as change in LV end-
systolic volume index. Relationships among galectin-3, biomarkers, and LV remodeling were analyzed across the entire 
cohort, then according to median baseline LV ejection fraction. Galectin-3 levels were elevated in 22 patients (22%) at 
baseline and increased significantly over time from 14.7±5.5 to 16.3±6.6 ng/mL (P=0.007). Baseline galectin-3 did not 
correlate with any LV parameters at baseline or change in any parameter over time. Galectin-3 was positively associated 
with remodeling in patients with supramedian baseline LV ejection fraction (ie, >49.2%; r=0.40; P=0.01) but not when 
LV ejection fraction was ≤49.2%. Galectin-3 correlated significantly with matrix metalloproteinase-3 and monocyte 
chemoattractant protein-1 at baseline, biomarkers that have been shown to relate to LV remodeling in this cohort.
Conclusions—Galectin-3 correlated significantly with certain biomarkers involved in extracellular matrix turnover, although 
no definite relationship was identified with LV remodeling. Whether galectin-3 plays a pathological role in remodeling 
remains unclear but merits further study.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00132093. (Circ Heart Fail. 
2013;6:492-498.)
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galectin-3 is increased in patients with acutely decompensated 
heart failure, whereas elevated serum galectin-3 levels in 
patients with chronic heart failure (CHF) are associated with 
higher New York Heart Association class and predict poorer 
outcome.10–12 Correlation between serum galectin-3 and 
echocardiographic measures of diastolic function and right 
ventricular performance has been demonstrated in patients 
with dyspnoea with and without acutely decompensated 
heart failure, but detailed cardiac structural data in relation to 
galectin-3 levels are lacking.13 Moreover, there are no human 
studies examining the role of galectin-3 in LV remodeling after 
AMI. We measured galectin-3 on plasma samples from a cohort 
of patients admitted with AMI and enrolled in a randomized 
trial assessing the effects of aldosterone antagonism on LV 
remodeling, and present data on the relationships over time 
of plasma galectin-3 and cardiac structural and functional 
parameters, using cardiac MRI (CMR).14
Methods
Patients
The subjects of this study were participants in a randomized, double-
blinded, placebo-controlled clinical trial investigating the effects of 
eplerenone on LV remodeling after AMI.14 Inclusion criteria were 
aged ≥18 years; able to provide written, informed consent; AMI 
1 to 14 days before enrollment; screening transthoracic echocar-
diographic LV ejection fraction (LVEF) <40% (Simpson biplane 
rule). The main exclusion criteria were clinical or radiological heart 
failure (Killip score >I), diabetes mellitus, pregnancy, serum cre-
atinine >220 μmol/L (≈2.5 mg/dL), serum potassium >5.0 mmol/L, 
planned coronary artery bypass surgery, contraindication to CMR. 
The trial protocol complied with the declaration of Helsinki and was 
approved by the local ethics committee.
Methods
At baseline, eligible patients had venous blood collected for measure-
ment of blood chemistry and biomarker concentrations (including 
galectin-3), after which contrast-enhanced CMR (ceCMR) was per-
formed. Patients were then randomized to double-blind eplerenone or 
placebo, with repeat ceCMR and measurement of plasma biomarkers 
at 24 weeks after which study drug was withdrawn and individual 
patient involvement in the trial ceased.
Measurement of Galectin-3
For galectin-3 measurement, we used an enzyme-linked immunosor-
bent assay developed by BG Medicine, Inc, Waltham, MA, which 
quantitatively measures galectin-3 concentrations on plasma samples. 
At both time-points, blood was collected into chilled tubes containing 
potassium EDTA (1 mg/mL blood) and aprotinin (50 KIU/mL blood), 
and centrifuged within 1 hour at 2000 g for 15 minutes at ambient 
temperature. Plasma was extracted and stored at −70°C until batched 
blinded analysis after trial completion. Each aliquot was subjected to 
2 freeze–thaw cycles. The coefficient of variation (CV) for the assay 
was <10%, and the limit of detection was 1.13 ng/mL.
Measurement of Other Biomarkers
Blood similarly collected into chilled tubes containing potassium 
EDTA and aprotinin, and centrifuged within 1 hour before plasma 
extraction and stored at −70°C was used for quantification of ma-
trix metalloproteinases (MMP-2, -3, and -9), tissue inhibitors of 
metalloproteinase (TIMP-1, -2, and -4), and N-terminal pro-B-type 
natriuretic peptide (NT-proBNP). Each aliquot was subjected to 1 
freeze–thaw cycle only. The MMPs and TIMPs were measured us-
ing commercially available enzyme-linked immunosorbent assay 
kits (R&D Systems, Abingdon, Oxfordshire, United Kingdom). The 
intra- and interassay CV was <10% for each assay. NT-proBNP was 
measured using a chemiluminescent assay kit (Roche Diagnostics) on 
an Elecsys 2010 autoanalyzer (CV<2%; limit of detection, 5 pg/mL).
Blood simultaneously collected into plain tubes, allowed to clot, 
then centrifuged at 2000 g for 15 minutes at ambient temperature 
before serum extraction and stored at −70°C was used to measure 
several biomarkers. Serum cytokines were analyzed in a 20-plex hu-
man cytokine assay (Biosource, Invitrogen) for simultaneous quan-
tification of interleukin-1 (IL-1) receptor antagonist (IL-1Ra), IL-2 
receptor (IL-2R), IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40), 
IL-15, IL-21, and monocyte chemoattractant protein-1. This assay 
was run according to the manufacturer’s procedure and read on the 
Bio-Plex suspension array system (CV<5%). Serum soluble ST2 
(sST2) was quantified using a human IL-1 R4/ST2 enzyme-linked 
immunosorbent assay (R&D Systems), with CV<5% and lower limit 
of detection of 32 pg/mL. Apelin quantification was performed using 
the Apelin-12 microplate enzyme-linked immunosorbent assay kit 
(Phoenix Pharmaceuticals) according to the manufacturer’s instruc-
tions (CV<5%).
ceCMR Protocol and Analysis
ceCMR was performed using a 1.5T Siemens Sonata with a phased-
array chest coil, during breath-hold, and gated to the ECG. The se-
quences used in cine image acquisition and in inversion-recovery 
imaging after administration of gadolinium diethylenetriaminepen-
taacetate (GE Healthcare), together with the techniques used in mea-
suring LV volumes, LVEF and infarct volumes, have been described 
in detail previously.14
Statistics
ceCMR measurements were adjusted for total body surface area, 
creating the following indexed quantities: LV end-systolic volume 
index (LVESVI), LV end-diastolic volume index (LVEDVI), LV 
mass index, and LV infarct volume index. Only patients with both 
a baseline and 24-week follow-up scan were analyzed; patients with 
an incomplete dataset were excluded. LV remodeling was defined 
as the change in LVESVI between baseline and 24 weeks because 
this is more strongly predictive of adverse cardiovascular outcome 
than change in LVEDVI (or even change in LVEF).4 All baseline bio-
marker measurements were taken before randomization, and serial 
biomarker data were analyzed regardless of parent study treatment 
allocation; galectin-3 data were then analyzed by treatment group. 
Normally distributed, continuous data are expressed as mean values 
(±SD). Non-normally distributed continuous data are expressed as 
medians (interquartile range). Differences between mean values were 
analyzed using the Student t test and those between median values by 
the Mann–Whitney U test. Paired comparisons in biomarker concen-
trations over time were performed using the Wilcoxon match-pairs 
signed-rank test. The biomarker data were non-normally distributed 
and thus were logarithmic-transformed before correlative analy-
sis. Bonferroni post hoc correction was applied to comparisons of 
mean concentrations of galectin-3 and the sampled biomarkers listed 
above; where quoted, the P values for such comparisons are (SPSS) 
Bonferroni-corrected. Spearman correlation coefficients were used to 
assess the relationships between biomarker values and ceCMR pa-
rameters of LV function.
Given that galectin-3 is a more powerful prognostic marker in 
CHF with preserved LVEF (HF-PEF) than in CHF with reduced 
LVEF (HF-REF),12 we categorized LVEF at baseline according to 
median LVEF, then analyzed the relationship between galectin-3 and 
remodeling in relation to median baseline LVEF. To test for interac-
tion between baseline galectin-3, LVEF, and remodeling in each of 
these 2 subgroups (baseline LVEF≤median, baseline LVEF>median), 
linear regression analysis was performed with baseline LVEF, galec-
tin-3, and an interaction quotient—defined as the product of baseline 
LVEF and galectin-3—inserted as independent variables to assess the 
effects on change in LVESVI in each group. All statistical analyses 
were performed using SPSS version 15.0 (SPSS Inc, Chicago, IL). A 
P value of <0.05 was considered significant.
 by guest on July 6, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
494  Circ Heart Fail  May 2013
Results
Baseline characteristics are shown in Table 1. The mean time 
from AMI to screening transthoracic echocardiographic was 
34 hours, and to the first ceCMR scan was 97 hours; bio-
marker sampling was performed at a mean 46 hours after AMI 
and again at 24 weeks. Paired analysis of both ceCMR and 
biomarker results was performed in the 93 patients who com-
pleted the entire 24-week follow-up (3 died, 4 withdrew).
Galectin-3 Levels
For all study subjects (n=100) at baseline, mean plasma 
galectin-3 concentration was 14.7±5.4 (SD) ng/mL. Twenty-
two patients (22%) had galectin-3 levels above the upper 
limit of normal cut-off value for galectin-3 of 17.7 ng/mL. 
Higher galectin-3 concentrations were associated with older 
age (r=0.29; P=0.004), higher serum creatinine (r=0.39; 
P<0.001), and (weakly) with the use of an angiotensin-
converting enzyme inhibitor at baseline (r=0.20; P=0.049). 
Paired analysis of galectin-3 concentrations in the 93 patients 
who completed the study revealed a significant increase in 
plasma galectin-3 between baseline and 24 weeks, from 
14.7±5.5 to 16.3±6.6 ng/mL (P=0.007). During the same time 
period, serum creatinine was unchanged (100.0±21.3 μmol/L 
at baseline; 98.8±21.6 μmol/L at 24 weeks; P=0.46).
Galectin-3 and LV Function
Across the cohort, LVEF increased significantly between 
baseline and 24 weeks, from 48.9 (8.8)% to 52.9 (11.9)%, 
P<0.001. Baseline galectin-3 had no correlation with baseline 
CMR measurements: LVESVI (r=0.02; P=0.083), LVEDVI 
(r=0.01; P=0.95), LVEF (r=−0.14; P=0.16), or infarct vol-
ume index (r=0.10; P=0.34). Similarly, there were no sig-
nificant relationships between baseline galectin-3 and change 
from baseline to 24 weeks in any CMR measure (∆LVESVI, 
∆LVEDVI, ∆LVEF, or ∆infarct volume index). When ana-
lyzed in relation to 24-week values of these CMR parameters, 
baseline galectin-3 displayed inverse correlation with 24-week 
LVEF (r=−0.25; P=0.023) but not with any other parameter. 
Change in galectin-3 from baseline to 24 weeks had no asso-
ciation with the change in any LV or infarct volume measure-
ment over time (Figure).
Median LVEF was 49.2%. The relationships between 
galectin-3 and remodeling were analyzed according to 
whether baseline LVEF was >49.2% or ≤49.2%. In patients 
with supramedian LVEF at baseline, galectin-3 increased 
significantly from 13.9±4.3 to 15.5±5.3 ng/mL (P=0.016), 
whereas in those with baseline LVEF≤49.2%, galectin-3 was 
15.5±6.4 ng/mL at baseline and 17.0±7.7 ng/mL at 24 weeks 
(P=0.11). There were no significant associations between 
baseline galectin-3 and ∆LVESVI (ie, remodeling, r=0.1; 
P=0.46), ∆LVEDVI (r=0.02; P=0.91), or change in any other 
LV parameter over time in patients with LVEF≤49.2%. In 
those with supramedian LVEF at baseline, however, galectin-3 
correlated significantly with both ∆LVESVI (r=0.40; P=0.01) 
and ∆LVEDVI (r=0.42; P=0.008) but not with change in 
any other parameter. In patients with baseline LVEF≤49.2%, 
interaction tests revealed no significant relationships between 
∆LVESVI and baseline galectin-3 (β=−2.3; P=0.10), baseline 
LVEF (β=−0.45; P=0.27), or the galectin-3/LVEF interac-
tion coefficient (β=0.26; P=0.09). In the subgroup of patients 
with baseline LVEF>49.2%, however, galectin-3 remained a 
 significant predictor of ∆LVESVI (β=2.7; P=0.04); the rela-
tionship between ∆LVESVI and the galectin-3/LVEF inter-
action coefficient was of borderline statistical significance 
Table 1. Baseline Characteristics of Study Patients
Total Cohort (n=100) r* P*
Patient characteristics
 Age, y 58.9 (12.0) 0.29 0.004
 Male, % 77 (77%) 0.15 0.13
 BMI 30.8 (4.2) −0.08 0.42
Medical history
 Angina 39 (39%) 0.08 0.43
 Smoker 55 (55%) −0.07 0.49
 Previous AMI 7 (7%) 0.02 0.83
 Hypertension 35 (35%) 0.11 0.27
 Hypercholesterolemia 25 (25%) −0.11 0.26
Treatment
 Thrombolysis 54 (54%) −0.13 0.19
 Primary PCI 27 (27%) 0.05 0.62
 Rescue PCI 26 (26%) −0.02 0.82
 Angiography performed 85 (85%) −0.10 0.32
 PCI performed 74 (74%) −0.10 0.33
ceCMR measurements
 LVESVI, mL/m2 43.8 (15.2) 0.04 0.68
 LVEDVI, mL/m2 84.3 (18.1) 0.03 0.72
 ∆LVEF, % 48.9 (8.7) −0.10 0.33
 LVMI, g/m2 74.4 (14.9) 0.10 0.36
 Infarct volume, mL/m2 33.2 (20.7) 0.03 0.75
Renal function
 Creatinine, μmol/L 100.1 (21.3) 0.39 <0.001
Admission medication
 Aspirin 25 (25%) 0.17 0.09
 β-Blocker 18 (18%) 0.06 0.55
 ACE inhibitor/ARB 12 (12%) 0.20 0.049
 Statin 15 (15%) −0.05 0.59
Discharge medication
 Aspirin 96 (96%) 0.22 0.03
 Clopidogrel 82 (82%) 0.18 0.07
 β-Blocker 93 (93%) −0.12 0.23
 ACE inhibitor/ARB 94 (94%) 0.19 0.05
 Statin 98 (98%) −0.06 0.52
 Furosemide 21 (21%) 0.17 0.09
Continuous data are expressed as mean (SD), whereas categorical data are 
expressed as percentages of the cohort at baseline. ACE indicates angiotensin-
converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin receptor 
blocker; BMI, body mass index; ceCMR, contrast-enhanced CMR; LVEDVI, LV end-
diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, LV end-systolic 
volume index; LVMI, LV mass index; and PCI, percutaneous coronary intervention.
*Correlative analysis with baseline galectin-3 (Spearman correlation coefficients 
for continuous variables, or paired samples correlation for categorical variables).
∆ Normal range 58% to 68%.
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(β=−2.5; P=0.05). Baseline LVEF was not a significant pre-
dictor of ∆LVESVI in this subgroup (β=0.75; P=0.10).
Galectin-3 and Natriuretic Peptides
NT-proBNP fell from 2587 (2732) pg/mL at baseline to 841 
(1982) pg/mL at 24 weeks (P<0.001). Baseline galectin-3 cor-
related with baseline NT-proBNP (r=0.30; P=0.003) and with 
∆NT-proBNP (r=−0.24; P=0.022).
Galectin-3 and Biomarkers
Correlative analysis of galectin-3 concentrations and the 
sampled biomarkers is detailed in Table 2. At baseline, 
there was significant correlation between galectin-3 and 
MMP-3, TIMP-1, monocyte chemoattractant protein-1, 
and IL-8. The only parameter that correlated significantly 
with change over time in galectin-3 was change in apelin 
concentration.
Figure. Mean (±SEM) change from baseline in galectin-3 concentration in relation to (A) left ventricular end-systolic volume index 
(∆LVESVI) and LV end-diastolic volume index (∆LVEDVI), (B) LV ejection fraction (∆LVEF), (C) LV infarct volume index, and (D) LV mass 
index. Correlation coefficients and significance levels are shown for each cardiac magnetic resonance parameter in relation to change in 
galectin-3.
Table 2. Spearman Correlation Coefficients for Biomarkers, Sampled at Baseline and 24 Weeks, and Simultaneous Galectin-3 
Concentrations During 24 Weeks Post-AMI in the 93 Patients Who Completed the Study
Gal-3 MMP-2 MMP-3 MMP-9 TIMP-1 TIMP-2 TIMP-4 sST2 Apelin IL-1Ra IL-2R IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12 IL-15 IL-21 MCP-1
Baseline 
line
0.05 0.33** 0.18 0.22* 0.15 0.18 −0.15 0.01 0.03 0.18 0.38 0.16 0.05 0.15 0.34** −0.02 0.18 0.10 0.04 0.23*
24 wk 0.02 0.22* 0.08 0.25* 0.05 0.24* 0.32* 0.18 −0.06 0.03 −0.07 0.04 0.08 0.09 0.29* −0.10 0.13 0.05 −0.01 0.14
∆ 0.05 −0.11 −0.19 0.02 −0.09 0.12 0.12 0.24* 0.07 −0.06 −0.08 −0.06 −0.08 −0.01 −0.07 −0.01 0.18 −0.07 0.03 −0.03
AMI indicates acute myocardial infarction; Gal-3, galectin-3; IL, interleukin; MCP, monocyte chemoattractant protein; MMP, matrix metalloproteinases; sST2, Serum 
soluble ST2; and TIMP, tissue inhibitors of metalloproteinase.
∆ Change in each biomarker between baseline and 24 weeks. Note: all biomarker data logarithmic-transformed before correlative analysis.
*P<0.05.
**P<0.01 (P values are SPSS Bonferroni-adjusted).
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Effect of Eplerenone on Galectin-3
At baseline, serum galectin-3 was 14.0 (4.6) ng/mL in 
patients randomized to placebo and 15.3 (6.0) ng/mL in 
those randomized to eplerenone (P=0.26). There was a non-
significant trend toward increase in galectin-3 in the placebo 
group (+1.1 [4.4] ng/mL; P=0.074), whereas the increase in 
galectin-3 levels in eplerenone-treated patients reached sig-
nificance (+2.1 [6.7] ng/mL; P=0.039). There was no sig-
nificant treatment effect of eplerenone on serum galectin-3 
levels during the 24-week study period (P=0.23). In the par-
ent study, eplerenone had a modest antiremodeling effect, but 
only after covariate adjustment.14
Discussion
A potential role for galectin-3 in the pathophysiology of LV 
remodeling has been suggested by a variety of animal and 
human studies, although a causal effect has yet to be proven. 
Data on circulating levels of galectin-3 in the early post-AMI 
period in humans are lacking, however, as are detailed car-
diac structural data in relation to galectin-3 concentrations in 
survivors of AMI and in patients with CHF. Galectin-3 has 
been shown to be elevated in 49% of a cohort of patients with 
New York Heart Association class III-IV CHF and reduced 
LVEF; levels of galectin-3 were unchanged over 6 months in 
a subset of these patients who underwent serial sampling.15 
Galectin-3 was similarly unchanged >18 months in patients 
with CHF, reduced LVEF, and interventricular conduction 
defects enrolled in the Cardiac Resynchronization in Heart 
Failure Trial (CARE-HF) trial.16 Among the novel findings in 
this study, we have shown that around one fifth of a cohort of 
patients admitted with AMI, with reduced LVEF at baseline, 
had an elevated plasma galectin-3 when sampled on average 
2 days after symptom onset. Moreover, despite a high revas-
cularization rate and greater uptake of antiremodeling drug 
therapy than any other post-AMI trial to date (reflected in 
the observation that LVEF rose significantly during the study 
follow-up and LV volumes decreased), plasma galectin-3 was 
found to increase significantly over time. Although this may 
suggest an uncoupling of galectin-3 and serial change in LV 
function, there were interesting observations when galectin-3 
levels were analyzed in relation to remodeling in this cohort.
We found that galectin-3 had no correlation with LVEF 
or LV volumes on the baseline CMR scan. This is consistent 
with echocardiographic studies in patients with CHF who 
have consistently failed to demonstrate any relationship 
between galectin-3 and LVEF; although, galectin-3 has been 
shown to correlate with parameters of LV stiffness (diastolic 
function) and right ventricular function in such patients.13,15 
However, subgroup analysis of patients stratified by median 
baseline LVEF revealed significant relationships between 
baseline galectin-3 and change in both LVESVI and LVEDVI 
over time in those with relatively preserved LV function early 
after AMI (ie, those with LVEF greater than the median) 
but not in those with median or lower baseline LVEF. This 
study was underpowered for biomarker analysis, and these 
findings may simply be spurious, or may simply reflect 
findings from a recent acute coronary syndromes study and a 
number of CHF trials that galectin-3 is an adverse prognostic 
marker.12,13,15,17 Galectin-3 has, however, been shown to 
be a more powerful prognostic indicator in patients with 
HF-PEF than in those with HF-REF.12 Galectin-3 is related 
to certain echocardiographic markers of diastolic but not 
systolic dysfunction.13 In the failure-prone hypertrophied rat 
heart, myocardial biopsy before development of overt heart 
failure showed that galectin-3 expression was highest in 
the rats that later developed heart failure.7 We have found a 
possible association between higher galectin-3 levels and 
greater remodeling in patients with relatively preserved LV 
function early after AMI but not in those with more severe LV 
dysfunction.
Why might galectin-3 seem to be of greater significance 
prognostically (and perhaps pathophysiologically) in patients 
with relatively preserved LV function in CHF (and possibly 
after AMI)? Galectin-3 has been demonstrated to be profibrotic 
in animal models. It is released by activated macrophages and 
is required for normal phagocytosis, but in pathological states, 
such as (experimental) myocarditis and myocardial hypertro-
phy (in murine and rat models), galectin-3 stimulates macro-
phage migration and may also stimulate cardiac fibroblastic 
proliferation.11,12,18 Infusion of galectin-3 into the pericardium 
of healthy rats promoted extensive myocardial fibrosis and 
progressive LV dysfunction, effects that were completely 
obviated by the antifibrotic agent N-acetyl-seryl-aspartyl-
lysyl-proline (Ac-SDKP).7,19 Although a profibrotic effect in 
human myocardium has yet to be confirmed, galectin-3 has 
been shown to correlate significantly with MMP-2, TIMP-1, 
and PIIINP, all markers of extracellular matrix turnover, in 
patients with HF-REF.20 In the current cohort, we have pre-
viously demonstrated associations among TIMP-4, MMP-3, 
monocyte chemoattractant protein-1 and sST2 and remodel-
ing; of these biomarkers, galectin-3 was significantly associ-
ated with MMP-3 and monocyte chemoattractant protein-1 
at baseline in the current analysis.14,21–23 Galectin-3 may 
thus influence a variety of separate pathways of extracellu-
lar matrix turnover, and may provide the link between mac-
rophage activation and fibrosis, although this requires further 
investigation. Whether galectin-3 may activate certain profi-
brotic, proremodeling pathways in patients with preserved LV 
function that, perhaps, are already highly activated (via other 
means) in those with depressed LV function is unknown, but 
clearly the determination of whether galectin-3 plays a defi-
nite role in remodeling merits further study.
NT-proBNP is elevated in symptomatic and asymptomatic 
LVSD and predicts mortality across all grades of CHF (both 
HF-REF and HF-PEF).24–26 It also predicts major adverse car-
diac events after AMI.27 NT-proBNP was elevated early after 
AMI in the present study, and although it decreased signifi-
cantly over time, remained elevated at 24 weeks. We found 
that galectin-3 correlated significantly with NT-proBNP 
at baseline. Similar findings have been reported after acute 
coronary syndromes and in patients with CHF.15,17,28 Baseline 
galectin-3 also correlated inversely with ∆NT-proBNP, 
although galectin-3 subsequently rose over time. This presum-
ably reflects the difference between the profibrotic effects of 
galectin-3 and the load-dependent nature of natriuretic peptide 
release, NT-proBNP (and BNP) tending to fall with reduction 
in myocardial stretch and in the presence of off-loading thera-
pies, such as angiotensin-converting enzyme inhibitors and 
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diuretics. Indeed, in patients with advanced CHF requiring 
LV assist device (LVAD) support, galectin-3 and BNP were 
significantly elevated at baseline, but while BNP fell signifi-
cantly after LVAD implantation, galectin-3 did not (although 
galectin-3 was highest in those who died).11
The present study is the first to date that has assessed the 
effect of antiremodeling drug therapy on galectin-3 levels—
in either AMI or CHF—in a randomized, controlled manner. 
We analyzed whether 24 weeks of therapy with eplerenone 
influenced plasma galectin-3 levels after AMI. The study 
was powered for CMR end points rather than drug effects on 
biomarkers. Within these confines, we found that galectin-3 
increased over 24 weeks in patients treated with eplerenone 
but not in those receiving placebo; although, overall the treat-
ment effect did not reach statistical significance. In a recent 
substudy of the Controlled Rosuvastatin Multinational Trial 
in Heart Failure (CORONA), use of an aldosterone antago-
nist was associated with higher concentrations of galectin-3 
in patients with chronic systolic heart failure.29 These data 
may suggest potential interplay between galectin-3 and the 
aldosterone pathway, although such findings would need to 
be explored in a larger, appropriately powered study. That the 
profibrotic effects of galectin-3 were blocked by Ac-SDKP in 
an experimental model of cardiac remodeling suggest that fur-
ther research is warranted into both the development and pos-
sible clinical applications of galectin-3-modifying therapy in 
the attempt to ameliorate remodeling in CHF and after AMI.19
Limitations
The main limitation of this study is that the clinical trial on 
which the current analysis is based was powered for CMR 
end points, not biomarker effects.14 The results are, therefore, 
hypothesis-generating only. It is, however, the only study 
using serial CMR scanning—the current gold standard imag-
ing modality for LVEF and LV volume measurement (and that 
allows significant sample size reduction compared with echo-
cardiography and other modalities)—in relation to galectin-3. 
We measured galectin-3 only once at baseline, on average 2 
days after AMI. It is not known whether galectin-3 levels fluc-
tuate in plasma early after AMI, or indeed during the 24-week 
period that served as follow-up in our study. Similar limita-
tions are relevant to studies of galectin-3 in CHF.12,13 Our find-
ings are applicable to patients with AMI and depressed LV 
function on echocardiography performed within 48 hours of 
infarction, and without clinical heart failure, and, therefore, 
cannot be extrapolated to all patients with AMI. We measured 
galectin-3 concentrations in plasma only, which provide no 
information on tissue levels. Finally, the correlations reported 
do not necessarily indicate direct biological relationships but 
do provide directions for further study.
Conclusions
This is, to our knowledge, the first study reporting serial 
galectin-3 concentrations in human plasma after AMI. 
Galectin-3 was elevated in only around one fifth of 
survivors of AMI with reduced LVEF. Higher galectin-3 
concentrations at baseline were significantly associated 
with lower LVEF at 24-week follow-up, although there 
was no significant relationship between galectin-3 and 
remodeling per se. Whether a relationship does exist 
between galectin-3 and remodeling after AMI remains 
unclear and will require to be analyzed further in larger, 
appropriately powered studies. Galectin-3 seems to be 
related to natriuretic peptides after AMI similar to findings 
from CHF trials, and correlated significantly with certain 
biomarkers involved in the inflammation-fibrosis cascade, 
although it remains unclear whether galectin-3 plays a 
direct role in remodeling. We found no significant effect 
of therapy with the aldosterone antagonist eplerenone 
on serum galectin-3 levels over 24 weeks after AMI in 
this (underpowered) study, but further projects assessing 
the effects on remodeling (and indeed on cardiovascular 
outcomes) of specific galectin-3-modifying therapies are 
undoubtedly warranted as we continue to target remodeling 
as a therapeutic strategy in both AMI and CHF.
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A major consequence of improved treatment of acute coronary syndromes is the emergence of an increasing cohort of 
survivors at high risk of progressive left ventricular (LV) remodeling and heart failure, with its attendant morbidity and 
(premature) mortality. Attenuation, or even reversal, of LV remodeling is a major focus of disease management in such 
patients, with significant resources spent identifying not only biomarker predictors, but also potential mediators of the pro-
cess. Galectin-3 has been demonstrated to predict adverse outcome in human chronic heart failure studies; intriguingly, data 
from animal studies suggest that it may also be integral to remodeling because of its profibrotic properties. Data on galectin-3 
after acute coronary syndromes in humans are scarce. Our article describes the relationships among galectin-3, LV func-
tion, remodeling, and a variety of biomarkers related to remodeling in a cohort of survivors of acute myocardial infarction. 
Our findings, that galectin-3 increases over time post–acute myocardial infarction (in contrast to stable chronic heart failure 
cohorts), that galectin-3 is related to lower medium-term LV ejection fraction, and that galectin-3 may potentially predict 
greater remodeling in patients with relatively preserved LV ejection fraction after acute myocardial infarction, add further 
weight to the growing body of evidence that suggests that this novel biomarker may play a role in the remodeling process, 
although, clearly further study is warranted. If a profibrotic role is confirmed in human myocardium after acute myocardial 
infarction and in chronic heart failure, there is the potential for trials assessing the use of galectin-3 modulating agents in 
ameliorating outcomes in these costly, highly morbid conditions.
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